This article is more than 5 years old. Information may no longer be current.

ThromboGenics completes enrollment for phase 3 MIVI-TRUST program

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LEUVEN, Belgium — ThromboGenics has completed enrollment for the second of two phase 3 trials involved in its MIVI-TRUST clinical program evaluating microplasmin for the nonsurgical treatment of focal vitreomacular adhesion, the company announced in a press release.

The randomized, placebo-controlled, double-masked TG-MV-007 trial has enrolled more than 320 patients in 48 centers in Europe and the United States to date.

This follows the company's September announcement that it had enrolled a total of 320 patients in its TG-MV-006 trial, the other arm of the MIVI-TRUST (Microplasmin for intravitreous injection-traction release without surgical treatment) clinical program. Both trials will evaluate 125-µg intravitreal injections of microplasmin against placebo for treating patients with focal vitreomacular adhesion.

"Microplasmin is key to the success of our ophthalmic focused strategy, and the speed at which patients have been recruited is encouraging," Patrik De Haes, MD, CEO of ThromboGenics, said in the release. "We very much look forward to announcing the first results from our MIVI-TRUST phase 3 program by mid 2010."

ThromboGenics expects to present results from both studies during the second and third quarters of 2010.